But the arrival of cheaper generics could be big news for countries where semaglutide usage is not yet mainstream
Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinsons disease
Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs
Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2
Wharton S, Blevins T, Connery L, et al
In the UK, approximately 28% of adults live with obesity, leading many to seek alternatives to injections, but current patch technology cant effectively deliver peptide hormones, like GLP-1, through the skin